Daclatasvir
Daklinza (daclatasvir) is a small molecule pharmaceutical. Daclatasvir was first approved as Daklinza on 2015-07-24. It is used to treat chronic hepatitis c and hepatitis c in the USA. Daklinza's patents are valid until 2031-06-13 (FDA).
| Trade Name | Daklinza |
|---|---|
| Common Name | Daclatasvir |
| Indication | chronic hepatitis c, hepatitis c |
| Drug Class | Antivirals: NS5A inhibitors |
